Recent Finacing
Recent Raise
Timberlyne develops CM313, an enhanced‑CDC IgG1 anti‑CD38 monoclonal antibody in clinical development for autoimmune diseases and relapsed/refractory multiple myeloma, holding development and commercialization rights outside greater China.
